Get the Stockscreener App
3.215
0.77%
-0.025
Xenetic Biosciences Inc stock is traded at $3.215, with a volume of 21,332.
It is down -0.77% in the last 24 hours and down -14.27% over the past month.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
See More
Previous Close:
$3.24
Open:
$3.18
24h Volume:
21,332
Relative Volume:
0.30
Market Cap:
$4.96M
Revenue:
$2.54M
Net Income/Loss:
$-4.13M
P/E Ratio:
-1.1691
EPS:
-2.75
Net Cash Flow:
$-4.11M
1W Performance:
-10.78%
1M Performance:
-14.27%
6M Performance:
-25.41%
1Y Performance:
-24.35%
1-Day Range:
$3.05
$3.4299
1-Week Range:
$3.05
$3.67
52-Week Range:
$2.20
$5.2683
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Name
Xenetic Biosciences Inc
Sector
Industry
Phone
781-778-7720
Address
945 CONCORD ST., FRAMINGHAM, MA
Compare XBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
3.215 | 5.00M | 2.54M | -4.13M | -4.11M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-20 | Initiated | Maxim Group | Buy |
Xenetic Biosciences Inc Stock (XBIO) Latest News
Is Xenetic Biosciences Inc. meeting your algorithmic filter criteriaPortfolio Safety Metrics and Return Analysis - Newser
Is Xenetic Biosciences Inc. a growth stock or a value stockEarnings Report Strategy With High Returns - jammulinksnews.com
How volatile is Xenetic Biosciences Inc. stock compared to the marketBest Dividend Review For Consistent Profits - jammulinksnews.com
Will Xenetic Biosciences Inc. benefit from macro trendsFree Trade Timing Strategy With Technical Data - Newser
Contrasting Redhill Biopharma (NASDAQ:RDHL) & Xenetic Biosciences (NASDAQ:XBIO) - Defense World
Top chart patterns to watch in Xenetic Biosciences Inc.Free Conservative Entry for High Return Setup - Newser
Xenetic Biosciences Inc. stock trend forecastFree Pattern Alert With ROI Driven Strategy - Newser
What makes Xenetic Biosciences Inc. stock price move sharplySmart Portfolio Data Feed For 2025 - jammulinksnews.com
Xenetic Biosciences Inc. stock outlook for YEARInvestment Strategy With Predictable Gains Outlined - metal.it
What machine learning models say about Xenetic Biosciences Inc.Free Trade Timing Strategy With Technical Data - Newser
Xenetic announces clinical study of DNase I with CAR T therapy By Investing.com - Investing.com South Africa
Xenetic announces clinical study of DNase I with CAR T therapy - Investing.com Australia
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma - Corsicana Daily Sun
New Clinical Trial Targets 60% Lymphoma Relapse Rate with Revolutionary DNase-CAR T Combination - Stock Titan
How Xenetic Biosciences Inc. stock performs during market volatilityAsset Growth Pattern and Return Summary - Newser
What are analysts’ price targets for Xenetic Biosciences Inc. in the next 12 monthsPost Market Review For 2025 - jammulinksnews.com
Is it the right time to buy Xenetic Biosciences Inc. stockInvest confidently with actionable market data - jammulinksnews.com
What are Xenetic Biosciences Inc. company’s key revenue driversFree Stock Market Return Analysis - jammulinksnews.com
Is Xenetic Biosciences Inc. stock overvalued or undervaluedOverwhelming profit margins - jammulinksnews.com
What catalysts could drive Xenetic Biosciences Inc. stock higher in 2025Build a diversified portfolio for risk management - jammulinksnews.com
Will Xenetic Biosciences Inc. benefit from macro trends Smart Trade Mapping with Entry Details - Newser
How many analysts rate Xenetic Biosciences Inc. as a “Buy”Maximize returns with strategic trading plans - jammulinksnews.com
What institutional investors are buying Xenetic Biosciences Inc. stockMarket-leading growth rates - jammulinksnews.com
What are the technical indicators suggesting about Xenetic Biosciences Inc.Skyrocketing investment returns - jammulinksnews.com
Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform - Chronicle-Tribune
When is Xenetic Biosciences Inc. stock expected to show significant growthSky-high profits - jammulinksnews.com
Buy Signal for Xenetic Biosciences Inc. Stock Key Technical Indicators to WatchReal Time Stock Signal - Newser
why xenetic biosciences inc. stock attracts strong analyst attentionROI Driven Alerts - Newser
Xenetic Biosciences Inc. Stock Analysis and ForecastPowerful profit generation - PrintWeekIndia
When is the best time to buy Xenetic Biosciences Inc. stockBreakthrough financial growth - jammulinksnews.com
What drives Xenetic Biosciences Inc. stock priceExceptional market performance - PrintWeekIndia
Xenetic Biosciences Inc Stock (XBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):